European Union - Maltese - EMA (European Medicines Agency)

teva b.v. - tacrolimus monohydrate - liver transplantation; kidney transplantation - immunosoppressanti - profilassi tar-rifjut tat-trapjanti f'riċevituri ta 'l-alloġib tal-kliewi jew tal-fwied adulti. kura ta 'rifjut tal-allograft reżistenti għat-trattament ma' prodotti mediċinali immunosoppressivi oħra f'pazjenti adulti.

European Union - Maltese - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

European Union - Maltese - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - aġenti antineoplastiċi - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

European Union - Maltese - EMA (European Medicines Agency)

idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - sleep inizjattiva u maintenance disorders - psikolettiċi - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

European Union - Maltese - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - preparazzjonijiet kardijaċi oħrajn - treatment of symptomatic obstructive hypertrophic cardiomyopathy.

European Union - Maltese - EMA (European Medicines Agency)

masitinib - tumur stromali gastrointestinali - inibituri tal-proteina kinase - it-trattament tal-jistax jitneħħa u/jew metastiku malinn tat-tumur stromali gastro-intestinali (gist).

European Union - Maltese - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - lewkimja, linfokitika, kronika, b-Ċellula - aġenti antineoplastiċi - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

European Union - Maltese - EMA (European Medicines Agency)

gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - antivirali għal użu sistemiku - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.

European Union - Maltese - EMA (European Medicines Agency)

amryt pharmaceuticals dac - lomitapide - iperkolesterolemija - aġenti li jimmodifikaw il-lipidi - lojuxta huwa indikat bħala frozen dieta low‑fat u lipid‑lowering prodotti mediċinali oħra jew mingħajru baxxa density-lipoprotein (ldl) aferesi fil-pazjenti adulti ma hypercholesterolaemia homozygous familjari (hofh). Ġenetiċi-konferma tal-hofh għandu jinkiseb kull meta jkun possibbli. - forom l-oħra tal-primarja hyperlipoproteinaemia u l-kawżi sekondarji ta ' l-iperkolesterolimja (e. sindromu nefrotiku, ipotirojdiżmu) għandhom jiġu esklużi.

European Union - Maltese - EMA (European Medicines Agency)

les laboratoires servier - pegaspargase - leukimija limfoblastika taċ-Ċelluli prekursuri-linfoma - aġenti antineoplastiċi - oncaspar huwa indikat bħala komponent ta 'terapija kombinata antineoplastika fil-lewkimja limfoblastika akuta (all) f'pazjenti pedjatriċi minn twelid sa 18-il sena, u pazjenti adulti.